---
title: "Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Clinical trials questions"
description: "Clinical trials questions on Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: ASCENT trial, ASCENT-03 trial, and ASCENT-04 trial. Questions: How was the TRODELVY ASCENT trial in previously treated metastatic TNBC designed? TRODELVY vs chemotherapy in metastatic TNBC (ASCENT): what was median progression-free survival? How long did TRODELVY patients live compared with chemotherapy in metastatic TNBC (ASCENT)? How effective is first-line TRODELVY when PD-1/PD-L1 inhibitors are not an option (ASCENT-03)? 3 further questions follow. 7 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Clinical trials questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Trodelvy](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)

## ASCENT trial

<a id="trodelvy-ascent-design"></a>

### How was the TRODELVY ASCENT trial in previously treated metastatic TNBC designed?

> “ASCENT Study Design: ASCENT was a Phase 3, randomized, active-controlled, open-label study (N=529) in patients with unresectable locally advanced or mTNBC who had relapsed after at least 2 prior chemotherapies, at least one of them for metastatic disease. The efficacy analysis included PFS in brain-met–negative patients by BICR based on RECIST 1.1 criteria (primary endpoint), with PFS for the full population (all patients with and without brain metastases) and OS as secondary endpoints. Patients were randomized (1:1) to receive TRODELVY 10 mg/kg as an IV infusion on Days 1 and 8 of a 21-day cycle (n=267) or physician's choice of single-agent chemotherapy (n=262), which included eribulin, vinorelbine, gemcitabine, or capecitabine. Patients were treated until disease progression or unacceptable toxicity. 88% of patients in the full population were brain-met–negative.<sup>1,3</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=ASCENT%20Study%20Design%3A%20ASCENT%20was,in%20the%20full%20population%20were)

<a id="trodelvy-ascent-pfs"></a>

### TRODELVY vs chemotherapy in metastatic TNBC (ASCENT): what was median progression-free survival?

> “Primary endpoint: mPFS in the brain-met–negative population by BICR per RECIST 1.1 criteria<sup>1,a</sup>
>
> 5.6
>
> MONTHS
> with TRODELVY
>
> (95% CI: 4.3–6.3) (n=235)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=Primary%20endpoint%3A%20mPFS%20in%20the,%2895%25%20CI%3A%204.3%E2%80%936.3%29%20%28n%3D235%29)

> “1.7
>
> MONTHS
> with single-agent chemo
>
> (95% CI: 1.5–2.6) (n=233)
>
> HR: 0.41 (95% CI: 0.32–0.52); P<0.001”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=1.7,0.41%20%2895%25%20CI%3A%200.32%E2%80%930.52%29%3B%20P%3C0.001)

> “mPFS in the full population by BICR per RECIST 1.1 criteria<sup>1,a</sup>
>
> 4.8
>
> MONTHS
> with TRODELVY
>
> (95% CI: 4.1–5.8) (n=267)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=mPFS%20in%20the%20full%20population,%2895%25%20CI%3A%204.1%E2%80%935.8%29%20%28n%3D267%29)

On the page, select: Full Population PFS

> “1.7
>
> MONTHS
> with single-agent chemo
>
> (95% CI: 1.5–2.5) (n=262)
>
> HR: 0.43 (95% CI: 0.35–0.54); P<0.0001”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=1.7,0.43%20%2895%25%20CI%3A%200.35%E2%80%930.54%29%3B%20P%3C0.0001)

On the page, select: Full Population PFS

> “<sup>a</sup>PFS was defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever came first.<sup>1</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=was%20defined%20as%20the%20time,to%20any%20cause%2C%20whichever%20came)

Note: The full-population result appears under the Full Population PFS tab of the same page.

<a id="trodelvy-ascent-os"></a>

### How long did TRODELVY patients live compared with chemotherapy in metastatic TNBC (ASCENT)?

> “Secondary endpoint: mOS in the brain-met–negative population<sup>3</sup>
>
> 12.1
>
> MONTHS
> with TRODELVY
>
> (95% CI: 10.7–14.0) (n=235)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=Secondary%20endpoint%3A%20mOS%20in%20the,%2895%25%20CI%3A%2010.7%E2%80%9314.0%29%20%28n%3D235%29)

> “6.7
>
> MONTHS
> with single-agent chemo
>
> (95% CI: 5.8–7.7) (n=233)
>
> HR: 0.48 (95% CI: 0.38–0.59); P<0.001”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=6.7,0.48%20%2895%25%20CI%3A%200.38%E2%80%930.59%29%3B%20P%3C0.001)

> “mOS in the full population of ASCENT was 11.8 months with TRODELVY (95% CI: 10.5–13.8) vs 6.9 months with chemotherapy (95% CI: 5.9–7.6) (n=262); HR: 0.51 (95% CI: 0.41–0.62); P<0.0001<sup>1</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=mOS%20in%20the%20full%20population,HR%3A%200.51%20%2895%25%20CI%3A%200.41%E2%80%930.62%29%3B)

## ASCENT-03 trial

<a id="trodelvy-ascent03-pfs"></a>

### How effective is first-line TRODELVY when PD-1/PD-L1 inhibitors are not an option (ASCENT-03)?

> “ASCENT-03: A Phase 3, randomized, active-controlled, multicenter, open-label study (N=558) evaluating the efficacy and safety of TRODELVY vs 1L chemotherapies in patients with unresectable locally advanced or metastatic TNBC who had not received previous systemic therapy for advanced disease and who were not candidates for PD-1 or PD-L1 inhibitor therapy. Patients were randomized 1:1 to receive TRODELVY 10 mg/kg IV infusion on Days 1 and 8 of a 21-day cycle (n=279) or physician’s choice of chemotherapy (n=279), which included gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel. Patients were treated until disease progression, unacceptable toxicity, death, or consent withdrawal. Crossover to TRODELVY monotherapy was allowed at the time of disease progression and study treatment discontinuation. The primary endpoint of PFS was assessed by BICR per RECIST v1.1 criteria.<sup>1,2</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-progression-free-survival#:~:text=ASCENT%2D03%3A%20A%20Phase%203%2C%20randomized%2C,by%20BICR%20per%20RECIST%20v1.1)

> “Primary endpoint: PFS by BICR per RECIST 1.1 criteria (ITT population) in ASCENT-03<sup>1,a</sup>
>
> 9.7
>
> MONTHS
> mPFS with TRODELVY
>
> (95% CI: 8.1–11.1) (n=279)
>
> ~3 MONTHS LONGER
>
> VS
>
> 6.9
>
> MONTHS
> mPFS with chemotherapy
>
> (95% CI: 5.6–8.2) (n=279)
>
> HR=0.62<sup>b</sup> (95% CI: 0.50–0.77); P<0.0001”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-progression-free-survival#:~:text=Primary%20endpoint%3A%20PFS%20by%20BICR,%2895%25%20CI%3A%200.50%E2%80%930.77%29%3B%20P%3C0.0001)

> “In an exploratory analysis at prespecified time points, the 12-month PFS rate was 41% with TRODELVY (95% CI: 34–47) vs 24% with chemotherapy (95% CI: 19–30)<sup>2</sup>
>
> The results do not evaluate the entire time-to-event distribution and are considered descriptive. Thus, they require cautious interpretation and could represent chance findings.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-progression-free-survival#:~:text=In%20an%20exploratory%20analysis%20at,and%20could%20represent%20chance%20findings.)

> “OS data were immature at the time of interim analysis<sup>1,a</sup>
> Of the 179 patients from the TPC arm who received subsequent therapy, 82% (n=147) crossed over to TRODELVY<sup>2</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-progression-free-survival#:~:text=OS%20data%20were%20immature%20at,82%25%20%28n%3D147%29%20crossed%20over%20to)

<a id="trodelvy-ascent03-response"></a>

### What is the first-line TRODELVY response rate (ASCENT-03)?

> “50% ORR with TRODELVY (95% CI: 44–56; n/N=133/266) vs 47% ORR with chemotherapy (95% CI: 41–53; n/N=124/264)<sup>1,a</sup>
>
> CR: 7% with TRODELVY (n/N=19/266) vs 5% with chemotherapy (n/N=13/264)<sup>1</sup>
> PR: 43% with TRODELVY (n/N=114/266) vs 42% with chemotherapy (n/N=111/264)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-response-data#:~:text=50%25%20ORR%20with%20TRODELVY%20%2895%25,vs%2042%25%20with%20chemotherapy%20%28n%2FN%3D111%2F264%29)

> “Limitation: ORR was evaluated as part of the prespecified hierarchical testing procedure for ASCENT-03. Since an endpoint higher in the testing procedure was not mature, this data has not gone through formal statistical testing. Other endpoints shown were not included in the prespecified hierarchical testing procedure. Additionally, substantial censoring occurred in both treatment arms before median duration of response was reached. Thus, the results should be considered descriptive, require cautious interpretation, and could represent chance findings.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-response-data#:~:text=Limitation%3A%20ORR%20was%20evaluated%20as,and%20could%20represent%20chance%20findings.)

> “Assessed in patients with measurable disease at baseline.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-ineligible-response-data#:~:text=in%20patients%20with%20measurable%20disease%20at%20baseline.)

## ASCENT-04 trial

<a id="trodelvy-ascent04-pfs"></a>

### How effective was first-line TRODELVY plus pembrolizumab for PD-L1-positive metastatic TNBC (ASCENT-04)?

> “ASCENT-04: A Phase 3, randomized, active-controlled, multicenter, open-label study (N=443) evaluating the efficacy and safety of TRODELVY + pembrolizumab vs 1L chemotherapy + pembrolizumab in patients with unresectable locally advanced or mTNBC who had not received previous systemic therapy for advanced disease and whose tumors expressed PD-L1.<sup>a</sup> Patients were randomized 1:1 to receive TRODELVY 10 mg/kg IV infusion on Days 1 and 8 of 21-day cycles plus pembrolizumab 200 mg on Day 1 of 21-day cycles (n=221) or physician’s choice of chemotherapy (n=222), which included gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel, plus pembrolizumab 200 mg on Day 1 of 21-day cycles. Patients were treated until disease progression, unacceptable toxicity, death, or consent withdrawal. Crossover to TRODELVY monotherapy was allowed following disease progression and study treatment discontinuation. The primary endpoint of PFS was assessed by BICR per RECIST v1.1 criteria.<sup>1,3</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-progression-free-survival#:~:text=ASCENT%2D04%3A%20A%20Phase%203%2C%20randomized%2C,by%20BICR%20per%20RECIST%20v1.1)

> “Defined as CPS ≥10 according to the PD-L1 IHC 22C3 pharmDx assay.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-progression-free-survival#:~:text=as%20CPS%20%E2%89%A510%20according%20to%20the%20PD%2DL1%20IHC%2022C3%20pharmDx%20assay.)

> “Primary endpoint: PFS by BICR per RECIST 1.1 criteria (ITT population) in ASCENT-04<sup>1,c</sup>
>
> 11.2
>
> MONTHS
> mPFS with TRODELVY + pembrolizumab
>
> (95% CI: 9.3–16.7) (n=221)
>
> ~3 MONTHS LONGER
>
> VS
>
> 7.8
>
> MONTHS
> mPFS with chemotherapy + pembrolizumab
>
> (95% CI: 7.3–9.3) (n=222)
>
> HR=0.65<sup>b</sup> (95% CI:0.51–0.84); P=0.0009”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-progression-free-survival#:~:text=Primary%20endpoint%3A%20PFS%20by%20BICR,%2895%25%20CI%3A0.51%E2%80%930.84%29%3B%20P%3D0.0009)

> “In an exploratory analysis at prespecified time points, the 12-month PFS rate was 48% with TRODELVY + pembrolizumab (95% CI: 41–56) vs 33% with chemotherapy + pembrolizumab (95% CI: 26–40)<sup>2</sup>
>
> The results do not evaluate the entire time-to-event distribution and are considered descriptive. Thus, they require cautious interpretation and could represent chance findings.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-progression-free-survival#:~:text=In%20an%20exploratory%20analysis%20at,and%20could%20represent%20chance%20findings.)

> “OS data were immature at the time of interim analysis<sup>1,c</sup>
> Of the 119 patients from the TPC + pembrolizumab arm who received subsequent therapy, 81% (n=96) crossed over to TRODELVY monotherapy<sup>3</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-progression-free-survival#:~:text=OS%20data%20were%20immature%20at,%28n%3D96%29%20crossed%20over%20to%20TRODELVY)

Note: On this page the 12-month PFS sentence cites reference 2, which the page lists as the ASCENT-03 publication (Cortés et al., N Engl J Med 2025); the study design passage cites reference 3, the ASCENT-04 publication (Tolaney et al., N Engl J Med 2026).

<a id="trodelvy-ascent04-response"></a>

### What is the first-line TRODELVY plus pembrolizumab response rate (ASCENT-04)?

> “61% ORR with TRODELVY + pembrolizumab (95% CI: 55–68; n/N=128/210) vs 55% ORR with chemotherapy + pembrolizumab (95% CI: 48–62; n/N=117/213)<sup>1,a</sup>
>
> CR: 12% with TRODELVY + pembrolizumab (n/N=25/210) vs 8% with chemotherapy + pembrolizumab (n/N=17/213)<sup>1</sup>
> PR: 50% with TRODELVY + pembrolizumab (n/N=105/210) vs 47% with chemotherapy + pembrolizumab (n/N=100/213)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-response-data#:~:text=61%25%20ORR%20with%20TRODELVY%20%2B,with%20chemotherapy%20%2B%20pembrolizumab%20%28n%2FN%3D100%2F213%29)

> “Limitation: ORR was evaluated as part of the prespecified hierarchical testing procedure for ASCENT-04. Since an endpoint higher in the testing procedure was not mature, this data has not gone through formal statistical testing. Other endpoints shown were not included in the prespecified hierarchical testing procedure. Additionally, substantial censoring occurred in both treatment arms before median duration of response was reached. Thus, the results should be considered descriptive, require cautious interpretation, and could represent chance findings.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-response-data#:~:text=Limitation%3A%20ORR%20was%20evaluated%20as,and%20could%20represent%20chance%20findings.)

> “Assessed in patients with measurable disease at baseline.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/pd-l1-eligible-response-data#:~:text=in%20patients%20with%20measurable%20disease%20at%20baseline.)

## Related pages
- [Medical information: Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/pharmacology)
- [Real-world evidence](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/guidelines)
